CalciMedica and Telperian Collaborate to Apply AI in Auxora Clinical Trial Analysis

CalciMedica Inc., a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies for inflammatory and immunologic diseases, announced a collaboration with Telperian, a clinical trial intelligence company, to integrate Telperian’s artificial intelligence (AI) engine into the analysis of clinical trial data for Auxora, CalciMedica’s lead compound.

Partnership Focus

The collaboration will leverage Telperian’s AI, biostatistics, and domain expertise to analyze data from completed Auxora clinical trials, including:

• Phase 2b CARPO trial in patients with acute pancreatitis (AP) and systemic inflammatory response syndrome (SIRS)
• Phase 2 CARDEA trial in patients with severe COVID-19 pneumonia

Additionally, Telperian will use its platform to emulate historical critical care studies and identify patterns that may guide the design of a pivotal trial for Auxora. Insights gained will support CalciMedica’s regulatory discussions with the US Food and Drug Administration (FDA).

About Auxora

Auxora is a potent and selective small molecule CRAC channel inhibitor under development for acute inflammatory and immunologic illnesses. Its potential therapeutic applications include:

• Acute pancreatitis (AP)
• Severe COVID-19 pneumonia
• Acute kidney injury (AKI) with respiratory failure – currently being evaluated in the phase 2 KOURAGE trial, with data expected in early 2026

Rachel Leheny, Ph.D., CEO of CalciMedica, said:

"CARPO and CARDEA are two critical trials contributing to the strong body of evidence supporting Auxora as a potentially transformative treatment. Telperian’s advanced AI engine will allow us to refine our understanding of treatment effects across patient subgroups and enhance the design of our pivotal AP program."

Role of Telperian’s AI Platform

Telperian’s platform offers:

• Asynchronous review of statistical data in regulatory submissions
• Historical evidence-based design intelligence
• Novel patient subtyping methodologies
• Comprehensive study design expertise

Rick Landin, co-founder and CEO of Telperian, commented:

"Our AI tools will accelerate detailed insights into Auxora’s pharmacokinetics and therapeutic effects. This collaboration highlights the potential of AI to streamline clinical development and regulatory processes."

About the Companies

CalciMedica Inc. focuses on CRAC channel inhibition therapies to modulate immune responses and protect tissue cells from injury, aiming to address life-threatening inflammatory and immunologic diseases that currently lack approved treatments.

Telperian provides Statistical Lifecycle solutions for drug developers, automating and optimizing clinical trial design, data analysis, and regulatory submissions to reduce errors, costs, and delays.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!